NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock

by · The Markets Daily

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) CAO Louise Frederika Kooij sold 26,011 shares of the business’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $35.68, for a total value of $928,072.48. Following the completion of the sale, the chief accounting officer directly owned 15,000 shares in the company, valued at $535,200. This represents a 63.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Louise Frederika Kooij also recently made the following trade(s):

  • On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
  • On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.

NewAmsterdam Pharma Stock Down 0.7%

NewAmsterdam Pharma stock traded down $0.25 during midday trading on Monday, hitting $35.02. The company’s stock had a trading volume of 372,987 shares, compared to its average volume of 944,760. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The company has a market capitalization of $3.97 billion, a PE ratio of -17.08 and a beta of 0.05. The stock’s 50-day moving average price is $37.08 and its 200-day moving average price is $29.03.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. As a group, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAMS. Quarry LP purchased a new stake in NewAmsterdam Pharma in the 1st quarter worth about $25,000. Mather Group LLC. acquired a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of NewAmsterdam Pharma in the third quarter worth approximately $30,000. Wolverine Asset Management LLC acquired a new stake in shares of NewAmsterdam Pharma during the third quarter worth approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock worth $79,000 after purchasing an additional 662 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on NAMS. The Goldman Sachs Group raised their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Needham & Company LLC upped their target price on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Citigroup increased their price target on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. HC Wainwright started coverage on NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.90.

Get Our Latest Report on NAMS

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

See Also